Back to search results
NCT07633496

The Effect of Osteopathic Manipulative Techniques on Human Tear Composition

Enrolling by Invitation
NAAges 18+InterventionalBasic science
Lake Erie College of Osteopathic Medicine
~30 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Osteopathic Manipulative TreatmentSham

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total tear protein concentration
Measured over Baseline, 1 hour, and 1 week
+4 more outcomes measured

Conditions

No Disease or Condition is Being Directly Studied
The Focus of the Study in Healthy Volunteers

Explore related trials

Healthy Volunteers

NCT07633496

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Plaza 38 Medical Offices

    Erie, Pennsylvaniano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Duriancik, Ph.D. · PRINCIPAL_INVESTIGATOR · Lake Erie College of Osteopathic Medicine

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals older than 18 years of age at the time of enrollment
Individuals that understand the study procedures and provide voluntary, informed consent
Individuals willing and able to receive Osteopathic Manipulative Treatment

Exclusion

Individuals younger than 18 years of age
Individuals who are pregnant or lactating
Individuals with infection or inflammatory conditions
Individuals physically unable to receive Osteopathic Manipulative Treatment
Individuals with dental or oral infection or surgery within the preceding 30 days.

What this trial measures

  • Total tear protein concentrationBaseline, 1 hour, and 1 week

    Total protein concentration assessed using the bicinchoninic acid assay

  • Secretory Immunoglobulin A ConcentrationBaseline, 1 hour, and 1 week

    Human IgA, also known as human immunoglobulin A, is an antibody that is produced by the immune system in response to antigens. It is the most abundant immunoglobulin in mucosal secretions, such as saliva, tears, and breast milk, and plays a key role in defense against pathogens at mucosal surfaces. IgA works by binding to specific antigens and preventing them from entering the body's tissues. It can also activate complement and promote phagocytosis by immune cells. This protein typically represents 5-15% of total protein in tears.

  • Tumor necrosis factor - alpha (TNFa) concentrationBaseline, 1 hour, and 1 week

    TNF alpha is a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophage and bind to its receptors, TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. TNF alpha is involved in the regulation of immune cells, cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.

  • Lipocalin-1 concentrationBaseline, 1 hour, and 1 week

    The protein encoded by this gene belongs to the lipocalin family. Lipocalins are a group of extracellular proteins that are able to bind lipophiles by enclosure within their structures to minimize solvent contact. This protein may bind hydrophobic ligands and inhibit cysteine proteinases. This protein is also known as Tear Prealbumin and typically represents 15-25% of total protein in tears.

  • secreted Phospholipase A2 (type IIA) concentrationBaseline, 1 hour, and 1 week

    Phospholipases A2 (PLA2s) make up a superfamily of enzymes that hydrolyze the ester bond of phosphoglycerides at the sn-2 position to release free fatty acid and lysophospholipids. The sPLA2 responsible for the release of arachidonic acid in inflammation was believed to be Type IIA. Although recently discovered isoforms of PLA2 clearly contribute to the release of arachidonic acid, sPLA2 (Type IIA) continues to be a protein of interest in the field of inflammation.